EDITEditas Medicine, Inc.

$256M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+818.7% YoY

Gross Profit

$59M97.6% margin

Operating Income

-$24M-39.9% margin

Net Income

-$19M-31.4% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+1025.4%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$24M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$499M

Total Liabilities

$150M

Stockholders' Equity

$349M

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$7M	+818.7%
Gross Profit	$59M	-$45M	+228.9%
Operating Income	-$24M	-$63M	+62.2%
Net Income	-$19M	-$61M	+68.9%

EDIT Q4 2023 Earnings — Editas Medicine, Inc. Revenue & Financial Results | Market Cap Arena